CytoGenix Gene Silencing ssDNA Technology Patent Allowed in Europe and India
Complete the form below to unlock access to ALL audio articles.
CytoGenix, Inc. has received notices of allowances for grant of patent applications covering the technology for expressing ssDNA In Vivo, from the Indian and European Community Patent Offices.
These notices follow the previous notice of allowance for these applications from the Peoples Republic of China.
Filed in 1999 and 2000, these patents cover the company’s single-strand DNA expression system covered by a US patent and by several patent applications in major world markets.
Used in the company’s Simplivir™ anti-herpes and CY303 anti inflammation products, an ssDNA gene silencing compound is active in reducing tumors in a melanoma experimental animal model.
Dr. Yin Chen, CytoGenix, Inc. Vice President, Chief Scientific Officer and a co-inventor of the single-strand DNA expression technology, states, "This is another step in our intellectual property strategy for this technology."
"These countries offer significant market opportunities and we are seeking appropriate licensees and partners."
